CONFERENCE DAY ONE

8:00 am Check-In & Light Breakfast

8:50 am Chair’s Opening Remarks

  • Gilles Besin Chief Scientific Officer, Orbital Therapeutics

Optimizing Self-Amplifying RNA Construct Design to Achieve Greater Stability & Reduced Cytotoxicity for More Durable Therapies

9:00 am Engineering Sa-mRNA Structure to Improve Vaccine Product Stability & Functionality

  • Fei Lu Associate Director, CSL Seqirus

Synopsis

• We can modulate sa-mRNA structure properties through sequence design

• Stabilization of RNA structure leads to improved sa-mRNA stability in solution and in LNP

• Sa-mRNA stability and translation balance can be achieved through iterative design learning cycles

New Data

New Company

9:30 am Creating a Novel SaRNA Backbone to Improve Payload Expression & Cell Type Targeting

  • WILLIAM JIA Co-Founder & Chief Scientific Officer, Virogin Biotech Ltd

Synopsis

• Designing a saRNA backbone with reduced cytotoxicity to improve safety for saRNAbased therapeutics

• Uncovering a novel saRNA backbone which enhances payload expression by minimizing immunogenicity

• Achieving cell specific targeting and expression with this novel saRNA

10:00 am Morning Break & Speed Networking

Synopsis

This session is your opportunity to get face-to-face with many of the brightest minds working in the circular and self-amplifying RNA field, and establish meaningful business relationships to pursue for the rest of the conference

Leveraging AI & Analytical Methods to Improve RNA Design & Quality for More Potent Next Generation RNA Therapeutics

11:00 am Advancing Analytical Methods Enabling Circular RNA Pharmaceutical Preparedness

Synopsis

• Discuss strategies to develop new methods for circular RNA while leveraging platformed methods from linear mRNA where possible

• Review orthogonal analytical approaches for confirming identity of circular RNA and associated impurities

• Uncovering analytical methods for supporting quality control processes for circular RNA payloads

New Data

New Company

11:30 am Roundtable Discussion: Harnessing AI & Computational Modelling for Designing Circular & Self-Amplifying RNA Constructs with Improved Efficacy & Reduced Immunogenicity

Synopsis

• Navigating the potential of incorporating computational techniques in the discovery and development of RNA therapeutics

• Highlighting the use of AI and computational modelling into sequence design and immune response prediction for more efficacious therapeutics

• How to use AI to design RNA constructs which will translate well in vivo and create long lasting results?

12:15 pm Lunch & Networking

Navigating Delivery for Circular & Self-Amplifying RNAs to Achieve Specific Targeting Leading to Enhanced Potency

1:15 pm Developing Safe & Effective Delivery Technologies for Self-Amplifying RNA Vaccines & Therapeutics

Synopsis

• Discussing HDT bio’s LION™ delivery technology – a cationic nanocarrier that is structurally and functionally distinct from LNPs

• Leveraging LION for enabling saRNA encoded mAb therapies

• Thermostable formulations of saRNA vaccines

New Company

1:45 pm Deep-Dive Workshop: Accomplishing Improved Encapsulation & Targeting of RNA Therapeutics by Uncovering Innovative Delivery Strategies for More Potent & Effective Therapies

Synopsis

The largest bottleneck inhibiting the full potential of all RNA therapeutics is delivery. With self-amplifying and circular RNA payloads typically being larger than those of linear mRNA, this complicates their encapsulation. Therefore, during this workshop you will explore cutting-edge delivery strategies which enhance RNA stability, improve targeting precision, and optimize encapsulation for safe and specific tissue and cell targeting.

This session will deep dive into:

• Optimizing delivery strategies for efficient RNA encapsulation and specific tissue targeting

• Uncovering the promise of LNPs and AAVs for targeted delivery of circular and self-amplifying RNA therapeutics

• Delving into novel delivery vehicles for enhancing endosomal escape of RNA therapeutics

3:00 pm Afternoon Networking Break & Scientific Poster Session

Synopsis

Contribute to the conversation and share your cutting-edge research with your fellow RNA community to showcase your breakthrough discoveries to a vast audience of experts. Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

Optimizing Manufacturing & Circularization Strategies for Large-Scale Production of Pure Therapies for the Patients in Need

3:30 pm Roundtable Discussion: Navigating Manufacturing Challenges for Circular & Self-Amplifying RNA to Improve Scalability, Purity & Yield for Regulatory Approval

Synopsis

• Improving manufacturing processes for enabling large scale production of circular and self-amplifying RNA therapeutics

• Delving into best practices in manufacturing, scaling up and purification of next generation RNA therapeutics

• Discussing learnings which can be taken from the standard linear mRNA production process

4:15 pm Improving Scalability & Quality of Circular RNAs for Vaccine Development

  • Chijian Zuo Vice President, CureMed Biomedical Technology

Synopsis

• Highlighting novel methods for accurate and reliable circularization of the mRNA

• Uncovering methods for improving CMC of circular RNAs to enable large scale and high-quality production

• Showcasing advances in circular RNA for vaccines in animal medicine

New Data

New Company

4:45 pm Untangling the Impacts of Process & Manufacturing on Self-Amplifying RNA Quality & Aligning with Safety & Immunogenicity in vitro and in vivo

Synopsis

• Delving into self-amplifying RNA critical quality attributes to inform high-quality manufacturing

• Understanding impact of formulation on host response to self-amplifying RNA for more potent and efficacious therapeutics and vaccines

• Determining how self-amplifying RNA quality will impact safety and immunogenicity in vitro and in vivo

New Data

New Company

5:15 pm Chairs Closing Remarks & End of Conference Day One

  • Gilles Besin Chief Scientific Officer, Orbital Therapeutics